National Bank of Canada
IOVA icon

National Bank of Canada’s Iovance Biotherapeutics IOVA Stock Holding History

National Bank of Canada’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$407 Buy
+116
New +$371 ﹤0.01% 2754
2024
Q2 		– Sell
-5,100
Closed -$55.9K – 2764
2024
Q1 		$55.9K Buy
+5,100
New +$59.4K ﹤0.01% 1720
2022
Q3 		– Sell
-71,000
Closed -$784K – 2785
2022
Q2 		$784K Sell
71,000
-682,000
-91% -$8.94M ﹤0.01% 1087
2022
Q1 		$12.5M Buy
+753,000
New +$11.6M 0.04% 406

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

National Bank of Canada's IOVA Position: Q1 2026 in Review

National Bank of Canada opened a new position in Iovance Biotherapeutics (IOVA) in Q1 2026: 116 shares worth $407. The stake represents ﹤0.01% of the portfolio and ranks #2754 among its holdings. This is a return to the name: National Bank of Canada previously reported a position in IOVA as recently as Q1 2024.

National Bank of Canada first reported a position in IOVA in Q1 2022 and has held it in 4 quarters since. The position peaked at $12.5M in Q1 2022. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • National Bank of Canada held 116 shares of Iovance Biotherapeutics worth $407 as of Q1 2026.
  • Iovance Biotherapeutics was a new National Bank of Canada position in Q1 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2754 holding.
  • National Bank of Canada first reported a position in Iovance Biotherapeutics in Q1 2022 and has held it in 4 quarters since.
  • National Bank of Canada's Iovance Biotherapeutics position peaked at $12.5M in Q1 2022.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.